Ginkgo bioworks announces acquisition of massachusetts covid-19 testing provider project beacon covid-19 llc

Boston, jan. 19, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced the acquisition of project beacon covid-19 llc (project beacon), a boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of covid-19 testing. under the terms of the deal, ginkgo acquired project beacon's assets and will assume responsibility for project beacon's ongoing operations, providing covid-19 monitoring tools to communities in massachusetts and other areas.
DNA Ratings Summary
DNA Quant Ranking